Practical recommendations on incorporating new oral anticoagulants into routine practice.
作者： Hamed Daw , Michael Ghobrial , Jaskirat Randhawa , Nirosshan Thiruchelvam , Timothy Spiro
DOI:
关键词:
摘要: The use of new oral anticoagulants (NOACs) is expected to rise significantly in upcoming years. Therefore, it important understand the potential uses, side effects, and management these agents routine practice. NOACs have major pharmacologic advantages over warfarin, including a rapid onset offset action, fewer drug interactions, predictable pharmacokinetics. These are gaining popularity among both physicians patients because their ease administration advantage eliminating requirement for regular coagulation monitoring. work prevent treat thrombosis by targeting either thrombin (as with dabigatran) or factor Xa rivaroxaban apixaban). In this review, we discuss practical recommendations risks benefits incorporating them into
参考文章(54)
Birgitte Klindt Poulsen, Erik Lerkevang Grove, Steen Elkjaer Husted, New oral anticoagulants: a review of the literature with particular emphasis on patients with impaired renal function. Drugs. ,vol. 72, pp. 1739- 1753 ,(2012) , 10.2165/11635730-000000000-00000
I. PRAGST, S. H. ZEITLER, B. DOERR, F. J. KASPEREIT, E. HERZOG, G. DICKNEITE, J. van RYN, Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P/N) in a rabbit model Journal of Thrombosis and Haemostasis. ,vol. 10, pp. 1841- 1848 ,(2012) , 10.1111/J.1538-7836.2012.04859.X
Timolaos Rizos, Solveig Horstmann, Roland Veltkamp, Intracerebral bleeding in patients on antithrombotic agents. Seminars in Thrombosis and Hemostasis. ,vol. 39, pp. 963- 971 ,(2013) , 10.1055/S-0033-1357506
R.J. Friedman, O.E. Dahl, N. Rosencher, J.A. Caprini, A.A. Kurth, C.W. Francis, A. Clemens, S. Hantel, J.M. Schnee, B.I. Eriksson, Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials Thrombosis Research. ,vol. 126, pp. 175- 182 ,(2010) , 10.1016/J.THROMRES.2010.03.021
Felix Schiele, Joanne van Ryn, Keith Canada, Corey Newsome, Eliud Sepulveda, John Park, Herbert Nar, Tobias Litzenburger, None, A specific antidote for dabigatran: functional and structural characterization. Blood. ,vol. 121, pp. 3554- 3562 ,(2013) , 10.1182/BLOOD-2012-11-468207
Genmin Lu, Francis R DeGuzman, Stanley J Hollenbach, Mark J Karbarz, Keith Abe, Gail Lee, Peng Luan, Athiwat Hutchaleelaha, Mayuko Inagaki, Pamela B Conley, David R Phillips, Uma Sinha, A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa Nature Medicine. ,vol. 19, pp. 446- 451 ,(2013) , 10.1038/NM.3102
Shannon M. Bates, Jeffrey S. Ginsberg, Treatment of Deep-Vein Thrombosis New England Journal of Medicine. ,vol. 351, pp. 268- 277 ,(2004) , 10.1056/NEJMCP031676
V. Matti J. Säily, Anssi Pétas, Lotta Joutsi-Korhonen, Kimmo Taari, Riitta Lassila, Antti S. Rannikko, Dabigatran for thromboprophylaxis after robotic assisted laparoscopic prostatectomy: retrospective analysis of safety profile and effect on blood coagulation. Scandinavian Journal of Urology and Nephrology. ,vol. 48, pp. 153- 159 ,(2014) , 10.3109/21681805.2013.817482
Reinhold Kreutz, Pharmacokinetics and Pharmacodynamics of Rivaroxaban – An Oral, Direct Factor Xa Inhibitor Current Clinical Pharmacology. ,vol. 9, pp. 75- 83 ,(2014) , 10.2174/1574884708666131111204658
BI Eriksson, OE Dahl, N Rosencher, AA Kurth, C Niek van Dijk, SP Frostick, P Kälebo, AV Christiansen, S Hantel, R Hettiarachchi, J Schnee, HR Büller, Re-Model Study Group, None, Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. Journal of Thrombosis and Haemostasis. ,vol. 5, pp. 2178- 2185 ,(2007) , 10.1111/J.1538-7836.2007.02748.X